Alnylam Reinforces RNAi Leadership with New ATTR and Hypertension Data
Event summary
- Alnylam to present new clinical and real-world data at ESC Congress 2026 on ATTR and hypertension programs.
- HELIOS-B Phase 3 study data to highlight vutrisiran's efficacy in ATTR-CM patients on background stabilizer therapy.
- Zilebesiran Phase 2 subgroup analysis to show potential in uncontrolled hypertension when combined with diuretics.
- ESC Congress 2026 takes place August 28-31, 2026, in Munich, Germany.
The big picture
Alnylam's presentations at ESC Congress 2026 underscore its leadership in RNAi therapeutics, particularly in addressing transthyretin amyloidosis and hypertension. The company's focus on expanding clinical evidence for vutrisiran and advancing zilebesiran through development reflects broader industry trends toward precision medicine and cardiovascular risk reduction. With over 500,000 people estimated to live with ATTR worldwide, and hypertension being the leading preventable risk factor for cardiovascular disease, Alnylam's progress has significant market implications.
What we're watching
- Clinical Validation
- Whether the new HELIOS-B data will solidify vutrisiran's position as a leading ATTR-CM treatment.
- Pipeline Progress
- The pace at which zilebesiran advances through Phase 3 trials and its potential market impact.
- Regulatory Pathway
- How ESC data presentations may influence future regulatory decisions for both ATTR and hypertension programs.